Prognosis for Glioblastoma After Standard Stupp Protocol
For a glioblastoma patient who completes maximal safe resection followed by 60 Gy radiotherapy with concurrent temozolomide (75 mg/m² daily) and up to six cycles of adjuvant temozolomide (150-200 mg/m²), the median overall survival is approximately 14.6-15 months, with a 2-year survival rate of 26.5%. 1, 2
Survival Outcomes Based on Landmark Evidence
The prognosis is defined by the pivotal EORTC 26981-22981 trial (Stupp protocol), which established this regimen as standard of care 3, 4. This trial demonstrated:
- Median overall survival: 14.6 months with radiotherapy plus temozolomide versus 12.1 months with radiotherapy alone 1, 2
- Hazard ratio for death: 0.63 (95% CI: 0.52-0.75, P<0.001), representing a 37% reduction in mortality risk 1, 2
- 2-year survival rate: 26.5% with combined treatment versus 10.4% with radiotherapy alone 2
- Median progression-free survival: approximately 7-8 months 5, 6
Critical Prognostic Modifiers
Extent of Surgical Resection
The degree of tumor removal significantly impacts survival:
- Gross total resection: median OS 23.2 months
- Partial/subtotal resection: median OS 14.75 months
- Biopsy only: median OS 7.89 months (p<0.001) 6
This represents the single most powerful modifiable prognostic factor after molecular markers.
MGMT Promoter Methylation Status
MGMT promoter methylation is the most important molecular prognostic factor 4. Patients with methylated MGMT promoter derive substantially greater benefit from temozolomide, while those with unmethylated MGMT (representing >50% of cases) have markedly reduced chemotherapy efficacy 7. The guidelines emphasize that MGMT testing should guide treatment decisions, particularly in elderly or poor-performance patients 4.
Performance Status
Karnofsky Performance Score (KPS) independently predicts survival 6. Patients with intact neurologic function and higher KPS have superior outcomes, serving as a surrogate for lower tumor burden and earlier treatment initiation 8.
Completion of Adjuvant Therapy
Completing all 6 cycles of adjuvant temozolomide significantly improves survival (p<0.001 on multivariate analysis) 8, 9. This is a critical quality metric. Notably, extending beyond 6 cycles does not provide additional survival benefit 8.
Real-World Outcomes
Multiple institutional series confirm these survival estimates in unselected populations:
- Median OS ranges from 13-15.1 months 5, 8, 9, 6
- 1-year survival: approximately 44-54%
- Treatment completion rate: 80-81% of patients complete the full protocol 9, 6
Treatment Tolerability
The regimen demonstrates acceptable toxicity:
- Grade 3/4 hematologic toxicity: 7-19.8% of patients 1, 8, 2
- Treatment discontinuation rate: 6.1% during radiotherapy 6
- Most patients (80%) complete the full treatment course as scheduled 6
Important Clinical Caveats
Age considerations: For patients ≥70 years or those with poor performance status, hypofractionated radiotherapy (40 Gy in 15 fractions) with concurrent temozolomide represents an alternative standard, offering similar efficacy with reduced treatment burden 3, 4.
Tumor-treating fields: While the EF-14 trial showed improved survival when added to maintenance temozolomide, this remains controversial regarding cost-effectiveness and real-world applicability 4.
Resistance mechanisms: Over 50% of patients have unmethylated MGMT promoter, which substantially limits temozolomide efficacy and contributes to the overall poor prognosis 10, 7.
The prognosis remains universally poor despite optimal treatment, with virtually all patients experiencing disease progression. Early integration of palliative care and realistic prognostic discussions are essential components of comprehensive management 4.